Opthea Ltd (CKDXF) stock
CKDXFOTCBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as CYVNY
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Jun 30, 2025Last filing: 20-F on Sep 15, 2025Score 0/30
$0.01+0.00 (0.00%)
Close on Oct 19, 2026Market cap –P/E –Yield –
Opthea r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $126.83M, down 28.1% from the year before. The highest annual figure on record is $176.33M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $126.83M | -28.1% |
| FY2024 | Jun 30, 2024 | $176.33M | +36.9% |
| FY2023 | Jun 30, 2023 | $128.83M | +58.2% |
| FY2022 | Jun 30, 2022 | $81.45M | +214.6% |
| FY2021 | Jun 30, 2021 | $25.89M | +114.6% |
| FY2020 | Jun 30, 2020 | $12.06M | -46.2% |
| FY2019 | Jun 30, 2019 | $22.42M | – |
See a number that looks wrong?